Maravai LifeSciences will report Q1 2025 results on May 12, 2025, followed by a conference call.
Quiver AI Summary
Maravai LifeSciences, Inc. is set to release its first quarter 2025 financial and operating results on May 12, 2025, after the market closes. The company will host a conference call and webcast at 2:00 p.m. PT/5:00 p.m. ET on the same day for stakeholders to participate. Interested parties can join the call by dialing specific numbers provided or can access the webcast through the company's investor webpage. Maravai is recognized for supplying vital products that facilitate the development of drug therapies, diagnostics, and vaccines, and is a key provider in the areas of nucleic acid synthesis and biologics safety testing.
Potential Positives
- Maravai LifeSciences is scheduled to announce its first quarter 2025 financial and operating results, indicating transparency and commitment to shareholder communication.
- The company will host a conference call and webcast for stakeholders, reflecting its emphasis on investor relations and engagement.
- Maravai is positioned as a key player in the life sciences sector, providing essential products for drug therapies, diagnostics, and vaccines, which highlights its relevance and importance in the ongoing healthcare and biotech industries.
Potential Negatives
- None
FAQ
When will Maravai announce its first quarter 2025 results?
Maravai will announce its first quarter 2025 financial and operating results on May 12, 2025, after market close.
What time is the Maravai conference call?
The conference call will take place at 2:00 p.m. PT/5:00 p.m. ET on May 12, 2025.
How can I participate in the Maravai conference call?
You can participate by dialing (800) 343-4849 or (203) 518-9848 and referencing the Conference ID MARAVAI.
Where can I find the webcast for Maravai's conference call?
The live and archived webcast will be available in the "Investors" section of Maravai's website at https://investors.maravai.com.
What services does Maravai LifeSciences provide?
Maravai provides life science reagents and services for drug therapies, diagnostics, vaccines, and research on human diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MRVI Insider Trading Activity
$MRVI insiders have traded $MRVI stock on the open market 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $MRVI stock by insiders over the last 6 months:
- CARL HULL (See Remarks) purchased 175,000 shares for an estimated $987,000
- KURT ORESHACK (General Counsel) sold 25,000 shares for an estimated $125,750
- JOHN A DEFORD purchased 17,500 shares for an estimated $100,625
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MRVI Hedge Fund Activity
We have seen 87 institutional investors add shares of $MRVI stock to their portfolio, and 123 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALYESKA INVESTMENT GROUP, L.P. added 3,161,072 shares (+145.8%) to their portfolio in Q4 2024, for an estimated $17,227,842
- MARSHALL WACE, LLP added 2,763,072 shares (+17912.9%) to their portfolio in Q4 2024, for an estimated $15,058,742
- 12 WEST CAPITAL MANAGEMENT LP removed 2,419,844 shares (-17.3%) from their portfolio in Q4 2024, for an estimated $13,188,149
- MILLENNIUM MANAGEMENT LLC removed 2,418,051 shares (-55.9%) from their portfolio in Q4 2024, for an estimated $13,178,377
- PORTOLAN CAPITAL MANAGEMENT, LLC removed 1,792,529 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $9,769,283
- UBS GROUP AG added 1,717,771 shares (+736.1%) to their portfolio in Q4 2024, for an estimated $9,361,851
- POINT72 (DIFC) LTD removed 1,104,601 shares (-41.5%) from their portfolio in Q4 2024, for an estimated $6,020,075
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2025 financial and operating results after the market close on Monday, May 12, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
To participate in the conference call by telephone, dial (800) 343-4849 or (203) 518-9848 and reference Maravai LifeSciences, Conference ID MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com .
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
